Pharmaceuticals

Egrifta (Tesamorelin Acetate) Market Future Drivers Influencing Growth Through 2030

May 5, 2026May 5, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Egrifta (Tesamorelin Acetate) Market Over The 2026–2030 Period?

Throughout the historical timeframe, expansion was propelled by an increased occurrence of HIV-related lipodystrophy, the adverse reactions stemming from long-term antiretroviral therapy, the successful clinical verification of GHRH analogs, a heightened understanding of the dangers associated with visceral fat, and a persistent requirement for precise abdominal fat reduction.

Anticipated expansion during the forecast period is fueled by advancements in individualized HIV treatment, an expanding pipeline of peptide-based therapies, a growing rate of metabolic complication diagnoses, favorable reimbursement policies for specialized medications, and an emphasis on improving the long-term well-being of HIV patients.

Prominent trends expected during the forecast period encompass sustained-action peptide drugs, individualized therapy for lipodystrophy, a broadening of therapeutic applications for metabolic conditions, injectable treatments designed with the patient at the core, and greater acceptance of specialty biological drugs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20043&type=smp

What Key Factors Are Affecting The Egrifta (Tesamorelin Acetate) Market Demand?

A notable driver for the future expansion of the egrifta (tesamorelin acetate) market is the growing incidence of human immunodeficiency virus (HIV) cases. HIV cases denote instances where individuals become infected with HIV, progressively impairing their immune system. This increase in HIV can be partly attributed to inadequate awareness and educational efforts regarding preventive actions like condom usage and consistent testing, especially among demographics at higher risk. Egrifta promotes the secretion of growth hormone, which aids in reducing surplus visceral fat and enhancing body composition, thereby improving the general health and life quality of those living with HIV. As an illustration, in May 2024, data from the Minnesota Department of Health, a US-based state health agency, indicated that MDH documented 324 new HIV diagnoses in 2023, representing a 24% increase compared to 2022. Consequently, the expanding occurrence of human immunodeficiency virus (HIV) cases is propelling the growth of the egrifta (tesamorelin acetate) market.

How Is The Egrifta (Tesamorelin Acetate) Market Categorized Across Its Segment Groups?

The egrifta (tesamorelin acetate) market covered in this report is segmented –

1) By Clinical Indication: Human Immunodeficiency Virus (HIV)-Associated Lipodystrophy, Growth Hormone Deficiency, Abdominal Obesity, Metabolic Syndrome

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By End-Users: Hospitals, Specialized Clinics, Home Care

What Emerging Trends Are Seen In The Egrifta (Tesamorelin Acetate) Market?

The main trend in the egrifta (tesamorelin acetate) market centers on developing advanced synthetic peptide drugs to improve the efficacy of treatments for HIV-related lipodystrophy. These synthetic peptide drugs are artificially designed compounds created to deliver specific therapeutic effects by mimicking or enhancing the actions of naturally occurring peptides. For example, in December 2024, Theratechnologies Inc., a Canada-based biopharmaceutical company, announced the resumption of EGRIFTA SV production following a voluntary shutdown of its contract manufacturer’s facility due to FDA inspection observations. A newly manufactured batch has successfully completed quality control and is slated for release upon US Food and Drug Administration (FDA) approval of a prior approval supplement, with two additional batches currently in production. The company is actively managing inventory to meet patient demand until mid-January 2025 and is working with the FDA to prevent a shortage in 2025. EGRIFTA SV is distributed solely in the United States.

Which Firms Are Influencing Competition In The Egrifta (Tesamorelin Acetate) Market?

Major companies operating in the egrifta (tesamorelin acetate) market are Theratechnologies Inc.

Get The Full Egrifta (Tesamorelin Acetate) Market Report:

https://www.thebusinessresearchcompany.com/report/egrifta-tesamorelin-acetate-global-market-report

Which Region Leads The Egrifta (Tesamorelin Acetate) Market In Overall Market Size?

North America was the largest region in the egrifta (tesamorelin acetate) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the egrifta (tesamorelin acetate) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Egrifta (Tesamorelin Acetate) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/egrifta-tesamorelin-acetate-global-market-report

Browse Through More Reports Similar to the Global Egrifta (Tesamorelin Acetate) Market 2026, By The Business Research Company

Ethyl Acetate Market Report 2026

https://www.thebusinessresearchcompany.com/report/ethyl-acetate-global-market-report

Ethylene Vinyl Acetate Market Report 2026

https://www.thebusinessresearchcompany.com/report/ethylene-vinyl-acetate-global-market-report

Ecoa Esource And Clinical Trials Market Report 2026

https://www.thebusinessresearchcompany.com/report/ecoa-esource-and-clinical-trials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795